COEP (Coeptis Therapeutics Holdings) Days Sales Outstanding : 0.00 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings Days Sales Outstanding?

Coeptis Therapeutics Holdings's average Accounts Receivable for the three months ended in Sep. 2024 was $0.00 Mil. Coeptis Therapeutics Holdings's Revenue for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Coeptis Therapeutics Holdings's Days Sales Outstanding or its related term are showing as below:

During the past 4 years, Coeptis Therapeutics Holdings's highest Days Sales Outstanding was 259.03. The lowest was 107.07. And the median was 183.05.

COEP's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 70.69
* Ranked among companies with meaningful Days Sales Outstanding only.

Coeptis Therapeutics Holdings's Days Sales Outstanding stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).

Coeptis Therapeutics Holdings Days Sales Outstanding Historical Data

The historical data trend for Coeptis Therapeutics Holdings's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coeptis Therapeutics Holdings Days Sales Outstanding Chart

Coeptis Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

259.03

107.07

Coeptis Therapeutics Holdings Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Sales Outstanding	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Coeptis Therapeutics Holdings's Days Sales Outstanding

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coeptis Therapeutics Holdings's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's Days Sales Outstanding falls into.

Coeptis Therapeutics Holdings Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Coeptis Therapeutics Holdings's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.008	+	0)	/	1 )	/	0	*	365
=	0.008					/	0	*	365
=	N/A

Coeptis Therapeutics Holdings's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding (Q: Sep. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2024 )	+	Accounts Receivable (A: Sep. 2024 ))	/	count )	/	Revenue (A: Sep. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Coeptis Therapeutics Holdings (NAS:COEP) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Coeptis Therapeutics Holdings Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Coeptis Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

105 Bradford Road, Suite 420, Wexford, PA, USA, 15090

Website

https://www.coeptistx.com

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Executives

Tara Desilva	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick	director, 10 percent owner, officer: CEO and President	5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind	director	1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace	director, officer: VP of Operations	402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise	director, 10 percent owner, officer: Chief Financial Officer	801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps	director	105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy	officer: CFO and Secretary	206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc	10 percent owner	299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr.	10 percent owner	151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp	10 percent owner	299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019